Ryan Scott

Treatment with subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in the treatment of metastatic non–small cell lung cancer.

The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated approval of Dato-DXd.

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study May Proceed” letter from the FDA.

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from treatment with targeted therapies.

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with myelodysplastic syndromes.

The use of prophylactic tranexamic acid didn't lead to a reduction in blood transfusion for patients undergoing open radical cystectomy for bladder cancer.

Meta: ONCT-534 had a well-tolerated safety profile on a twice daily dosing schedule in relapsed/refractory metastatic castration-resistant prostate cancer.

The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk non–muscle-invasive bladder cancer.

Sarclisa, Velcade, Revlimid and dexamethasone improved progression-free survival in patients with multiple myeloma who were not eligible for transplant.

Adding Truqap to Faslodex improved outcomes in patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer.

Data showed that metabolic and genetic factors could contribute to aggressive tumors in Latin American and non-Hispanic White patients with breast cancer.

Keytruda plus the combination of Herceptin and chemotherapy led to an improvement in progression-free survival versus placebo plus Herceptin and chemotherapy in the first-line treatment of some patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa.